Detalhe da pesquisa
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068901
2.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857659
3.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997907
4.
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Future Oncol
; 2022 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36268941
5.
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean.
Lancet Oncol
; 22(11): e488-e500, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735818
6.
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward.
Lancet Oncol
; 22(11): e474-e487, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735817
7.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Lancet
; 396(10265): 1817-1828, 2020 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33278935
8.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966830
9.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 379(22): 2108-2121, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345906
10.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
11.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(1): 44-59, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786121
12.
The Lancet Breast Cancer Commission.
Lancet
; 403(10439): 1895-1950, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38636533
13.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867034
14.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 620, 2019 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31234810
15.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 517, 2019 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146717
16.
PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).
BMC Cancer
; 19(1): 5, 2019 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30606144
17.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146401
18.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Breast Cancer Res
; 19(1): 18, 2017 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28183331
19.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26874901
20.
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Gynecol Oncol
; 138(2): 272-7, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26026738